Randomized trial assesses steroid use as a clinical prognosticator in MOGAD patients, suggesting its significance.
To assess the strength of reported clinical prognosticators for developing relapsing myelin-oligodendrocyte-glycoprotein antibody associated disease (R-MOGAD) in 101 patients with MOGAD (86% with onset in adulthood) from three UK Specialist centres using a prospectively planned analysis design with validation analysis.
No takes yet. Share an insight, caveat, or question.
Tanasescu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: